.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Daiichi Sankyo
Healthtrust
AstraZeneca
Merck
Queensland Health
Julphar
Chubb
Argus Health

Generated: September 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,637,512 protect, and when does it expire?


Patent ► Subscribe protects LAMICTAL XR and is included in one NDA. There has been one Paragraph IV challenge on Lamictal XR.

This patent has forty patent family members in thirty countries.

Summary for Patent: ► Subscribe

Title:Formulations and method of treatment
Abstract: A sustained release formulation of lamotrigine or a pharmaceutically acceptable derivative thereof and methods of treatment and uses thereof.
Inventor(s): Buxton; Ian Richard (Mississauga, CA), Karolak; Wlodzimierz (Mississauga, CA), Maleki; Mehran (Mississauga, CA), Iyer; Vijay Mohan (Mississauga, CA)
Assignee: Glaxo Group Limited (Brentford, Middlesex, GB)
Application Number:10/726,752
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-001May 29, 2009ABRXYesNo► Subscribe► SubscribeY
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-002May 29, 2009ABRXYesYes► Subscribe► SubscribeY
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-003May 29, 2009ABRXYesNo► Subscribe► SubscribeY
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-004May 29, 2009ABRXYesYes► Subscribe► SubscribeY
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-006Jun 21, 2011ABRXYesNo► Subscribe► SubscribeY
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-005Apr 14, 2010ABRXYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0217492.8Jul 29, 2002
United Kingdom0217493.6Jul 29, 2002
United Kingdom0313801.3Jun 13, 2003

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina040709► Subscribe
Austria424827► Subscribe
Australia2003260336► Subscribe
Brazil0313148► Subscribe
Canada2493301► Subscribe
China100363007► Subscribe
China101229169► Subscribe
China1681509► Subscribe
Colombia5680405► Subscribe
Cyprus1109119► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
McKesson
Accenture
Cantor Fitzgerald
UBS
Colorcon
QuintilesIMS
Julphar
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot